Abstract: Salts of pentamidine, formulations containing such salts and the use of such salts of treatment or prophylaxis of pneumocystis carinii. Pentamidine gluconate and lactate has been discovered and found to have high water solubility while providing potentially less toxic alternatives to pentamidine isethionate, especially for aerosolized administration to patients suffering from acquired immunodeficiency syndrome, AIDS, or AIDS related complex, ARC.

Abstract: A mannitol-free lyophilized formulation of cyclophosphamide is disclosed. Sodium chloride is present as an excipient.

Abstract: Nitroglycerin injection that is free of the customary organic solvents and has an extended shelf life of at least 1 year, consisting essentially of water, lactose, and nitroglycerin. Sodium chloride or dextrose may be added during manufacture or upon diluting with an infusion. Commercially safe manufacture and stable dispersion are assured by mixing lactose adsorbate, containing nitroglycerin, with water at high shear so that no nitroglycerin droplets coalesce. Stability is maintained by filtering and filling operations using nonreactive, nonleaching, nonadsorptive materials.

Abstract: This invention relates to an injectable, stable, sterile aqueous solution of cisplatin in a unit dosage form in a sealed container, the solution being suitable for administration by the injection thereof into man upon the removal thereof from the container, the solution consisting of water and cisplatin, said solution having a concentration of cisplatin between about 0.1 and about 1.3 mg/mL, and a pH in the range of about 3.5 to about 5.0, the solution being substantially free of dissolved oxygen.

Abstract: Nitroglycerin injection that is free of the customary organic solvents and has an extended shelf life of at least 1 year, consisting essentially of water, lactose, and nitroglycerin. Sodium chloride or dextrose may be added during manufacture or upon diluting with an infusion. Commerically safe manufacture and stable dispersion are assured by mixing lactose adsorbate, containing nitroglycerin, with water at high shear so that no nitroglycerin droplets coalesce. Stability is maintained by filtering and filling operations using nonreactive, nonleaching, nonadsorptive materials.

Abstract: A storage-stable liquid oncolytic formulation of cyclophosphamide for parenteral administration is presented. Currently utilized lyophilized formulations have inherent diseconomies and increased hazard is associated with reconstitution. The liquid formulations of the present invention comprise a solution of cyclophosphamide with an organic polyol as cosolvent, which provide enhanced shelf-life and greater ease of administration. The polyol is either propylene glycol, polyethylene glycol or glyerol. The solution of cyclophosphamide is either aqueous, or in the case of propylene glycol may constitute 10-30% by weight of an alcohol.

Abstract: A pharmaceutical composition for parenteral administration is disclosed which comprises from about 0.01% to about 30% of a .beta.-adrenergic blocking compound of the formula ##STR1## wherein Ar represents a substituted or unsubstituted aromatic group or heterocyclic group; W represents alkylene of from 1 to about 10 carbon atoms; and B represents --NR.sub.2 COR.sub.1, --NR.sub.2 CONR.sub.1 R.sub.3, --NR.sub.2 SO.sub.2 R.sub.1, --NR.sub.2 SO.sub.2 NR.sub.2 R.sub.3, or --NR.sub.2 COOR.sub.1 wherein R.sub.1, R.sub.2 and R.sub.3 may be the same or different and may be hydrogen, alkyl, alkoxyalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or aralkyl, except that R.sub.1 is not hydrogen when B is --NR.sub.2 SO.sub.2 R.sub.1 or --NR.sub.2 COOR.sub.1, or R.sub.1 and R.sub.

Abstract: It has been found that indoprofen can be used in increased safety at its effective anti-inflammatory dose in humans and that the activity of indoprofen is greatly prolonged by microencapsulating microparticles of indoprofen in a solid protective coating of a cellulose ether such as ethylcellulose.